Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136226126> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3136226126 endingPage "S508" @default.
- W3136226126 startingPage "S507" @default.
- W3136226126 abstract "The improvement in the outcomes of patients with extensive-stage small cell lung cancer (SCLC) has been modest over past decades despite tremendous efforts made in optimising treatment outcomes as demonstrated in multiple trials. This review aims to investigate the trends in trial design, interpretation and magnitude of survival benefit described in phase III randomized controlled trials (RCTs) evaluating first-line systemic antineoplastic therapy in patients with extensive-stage SCLC over past two decades. We searched biomedical database for relevant trials published between 2000 and 2019. Descriptive statistics were used to summarize the patterns in trial design and interpretation for each time period (2000-2004, 2005-2009, 2010-2014 and 2015-2019). The Cochran-Armitage trend test was performed to test the changes over time in reporting the primary end point, quality of life (QoL) and trial interpretations. The F test was used to test the change over time in the trial sample size and the reported net survival benefit. The net survival benefit was defined as the difference in median survival time between experimental and control arms. Thirty-eight eligible trials were identified, involving 11,689 patients with 76 treatment arms. Overall survival (OS) was the most common primary end point of trials over the time periods (89% in 2000-2004; 87% in 2005-2009; 80% in 2010-2014; 78% in 2015-2019; P= 0.99). There was a trend toward fewer number of trials that included QoL outcomes (44% in 2000-2004; 60% in 2005-2009; 40% in 2010-2014; 11% in 2015-2019; P= 0.31). Out of the sixteen (42.1%) trials that reported positive conclusions, only seven (18.4%) trials met their primary endpoint; these observations remained stable over time (positive trial conclusion: P= 0.99; trials met their primary endpoint: P= 0.53). The trial sample sizes were increasing over time (median sample size: 154 in 2000-2004; 220 in 2005-2009; 370 in 2010-2014; 299 in 2015-2019; P= 0.08). A trend toward increasing magnitude of survival gain in positive trials was seen over time (1.1 months in 2000-2004; 0.65 months in 2005-2009; 1.6 months in 2010-2014; 2.0 months in 2015-2019; P= 0.92). There was no significant shift in the design, interpretation and survival outcomes of phase III randomized controlled trials of systemic antineoplastic therapy in extensive-stage small cell lung cancer over the past two decades. The use of quality of life outcomes is declining while the improvement in the magnitude of overall survival benefit is modest. More effective systemic agents are needed to improve both the survival and quality of life outcomes of these patients." @default.
- W3136226126 created "2021-03-29" @default.
- W3136226126 creator A5010751715 @default.
- W3136226126 creator A5026312862 @default.
- W3136226126 creator A5042993077 @default.
- W3136226126 creator A5065157802 @default.
- W3136226126 creator A5090088935 @default.
- W3136226126 date "2021-03-01" @default.
- W3136226126 modified "2023-10-12" @default.
- W3136226126 title "P48.20 Trends in Trial Design, Interpretation and Survival in Phase III Clinical Trials on Extensive-Stage SCLC Between 2000 and 2019" @default.
- W3136226126 doi "https://doi.org/10.1016/j.jtho.2021.01.890" @default.
- W3136226126 hasPublicationYear "2021" @default.
- W3136226126 type Work @default.
- W3136226126 sameAs 3136226126 @default.
- W3136226126 citedByCount "0" @default.
- W3136226126 crossrefType "journal-article" @default.
- W3136226126 hasAuthorship W3136226126A5010751715 @default.
- W3136226126 hasAuthorship W3136226126A5026312862 @default.
- W3136226126 hasAuthorship W3136226126A5042993077 @default.
- W3136226126 hasAuthorship W3136226126A5065157802 @default.
- W3136226126 hasAuthorship W3136226126A5090088935 @default.
- W3136226126 hasBestOaLocation W31362261261 @default.
- W3136226126 hasConcept C105795698 @default.
- W3136226126 hasConcept C126322002 @default.
- W3136226126 hasConcept C129848803 @default.
- W3136226126 hasConcept C146357865 @default.
- W3136226126 hasConcept C151730666 @default.
- W3136226126 hasConcept C159110408 @default.
- W3136226126 hasConcept C168563851 @default.
- W3136226126 hasConcept C203092338 @default.
- W3136226126 hasConcept C2779951463 @default.
- W3136226126 hasConcept C33923547 @default.
- W3136226126 hasConcept C535046627 @default.
- W3136226126 hasConcept C71924100 @default.
- W3136226126 hasConcept C86803240 @default.
- W3136226126 hasConceptScore W3136226126C105795698 @default.
- W3136226126 hasConceptScore W3136226126C126322002 @default.
- W3136226126 hasConceptScore W3136226126C129848803 @default.
- W3136226126 hasConceptScore W3136226126C146357865 @default.
- W3136226126 hasConceptScore W3136226126C151730666 @default.
- W3136226126 hasConceptScore W3136226126C159110408 @default.
- W3136226126 hasConceptScore W3136226126C168563851 @default.
- W3136226126 hasConceptScore W3136226126C203092338 @default.
- W3136226126 hasConceptScore W3136226126C2779951463 @default.
- W3136226126 hasConceptScore W3136226126C33923547 @default.
- W3136226126 hasConceptScore W3136226126C535046627 @default.
- W3136226126 hasConceptScore W3136226126C71924100 @default.
- W3136226126 hasConceptScore W3136226126C86803240 @default.
- W3136226126 hasIssue "3" @default.
- W3136226126 hasLocation W31362261261 @default.
- W3136226126 hasOpenAccess W3136226126 @default.
- W3136226126 hasPrimaryLocation W31362261261 @default.
- W3136226126 hasRelatedWork W1569663381 @default.
- W3136226126 hasRelatedWork W1997239045 @default.
- W3136226126 hasRelatedWork W2009370781 @default.
- W3136226126 hasRelatedWork W2091161920 @default.
- W3136226126 hasRelatedWork W2138201488 @default.
- W3136226126 hasRelatedWork W2726737679 @default.
- W3136226126 hasRelatedWork W2887282919 @default.
- W3136226126 hasRelatedWork W2955643247 @default.
- W3136226126 hasRelatedWork W3000343160 @default.
- W3136226126 hasRelatedWork W4255009214 @default.
- W3136226126 hasVolume "16" @default.
- W3136226126 isParatext "false" @default.
- W3136226126 isRetracted "false" @default.
- W3136226126 magId "3136226126" @default.
- W3136226126 workType "article" @default.